AstraZeneca Leads Bid for Abivax as Eli Lilly Waits in the Wings
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
/ 67 items
#LLY↓
Novo & Hims Partner on Ozempic & Wegovy – Lawsuit Dropped
Novo Nordisk and Hims & Hers end their legal battle and team up to offer FDA-approved Ozempic and Wegovy (injections and pills) on the Hims platform. Hims shifts its focus to branded GLP-1s with limited compounded options. Shares surge.
From Lawsuit to Love: Novo Nordisk Teams Up with Hims & Hers Again
Novo Nordisk is set to sell its popular weight-loss drugs like Wegovy on Hims & Hers platform soon, surprising many after a recent lawsuit over copycat versions. This could boost access and help both companies in the competitive obesity market.
GoodRx Launches Employer Program to Offer Zepbound at Just $449 a Month
GoodRx partners with Eli Lilly to help employers subsidize Zepbound KwikPen at a $449 monthly price. The new Employer Direct program reduces out-of-pocket costs for workers without overhauling health benefits.
FDA Cracks Down Hard — 30 Telehealth Companies Warned Over Compounded Ozempic & Zepbound Copies
The FDA sent warning letters to 30 telehealth companies for false claims about compounded GLP-1 drugs like semaglutide and tirzepatide.
Novo Nordisk Slashes Wegovy & Ozempic List Prices by Up to 50% — But Analysts Say It Won’t Dent Lilly’s Lead
Novo Nordisk slashes list prices for Wegovy, Ozempic & Rybelsus to $675/month starting Jan 2027—50% cut for Wegovy. Helps high-deductible plans, but BofA sees little threat to Eli Lilly’s GLP-1 lead.